Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biotechnology and laboratory services · Beijing, Beijing
About Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a Chinese biotechnology company headquartered in Beijing and listed on the Hong Kong Stock Exchange (HKEX: 02315), dedicated to antibody drug discovery with its own gene-editing technologies. Its official English website, loaded directly for this listing, presents it as an end-to-end partner from target discovery to IND submission.
Its core is the RenMice platforms — RenMab, RenLite, RenNano and RenTCR-mimic — genetically engineered mice that produce fully human monoclonal and bispecific antibodies, nanobodies and TCR mimics, with a library of more than one million sequences. Under the BioMice sub-brand it also offers more than 5,600 off-the-shelf animal and cell models, drug-target humanised models, and preclinical pharmacology and custom gene-editing services.
According to the company, it has signed over 450 therapeutic antibody agreements and completed more than 10,000 drug evaluation projects, with AAALAC-accredited facilities in Haimen (Jiangsu), Daxing (Beijing) and Boston. For pharmaceutical and biotech companies seeking antibody discovery and preclinical models from a single provider, it is one of China's reference CROs.
Its core is the RenMice platforms — RenMab, RenLite, RenNano and RenTCR-mimic — genetically engineered mice that produce fully human monoclonal and bispecific antibodies, nanobodies and TCR mimics, with a library of more than one million sequences. Under the BioMice sub-brand it also offers more than 5,600 off-the-shelf animal and cell models, drug-target humanised models, and preclinical pharmacology and custom gene-editing services.
According to the company, it has signed over 450 therapeutic antibody agreements and completed more than 10,000 drug evaluation projects, with AAALAC-accredited facilities in Haimen (Jiangsu), Daxing (Beijing) and Boston. For pharmaceutical and biotech companies seeking antibody discovery and preclinical models from a single provider, it is one of China's reference CROs.